Logo image of HOTH

HOTH THERAPEUTICS INC (HOTH) Stock Fundamental Analysis

NASDAQ:HOTH - Nasdaq - US44148G2049 - Common Stock - Currency: USD

1.305  -0.03 (-1.88%)

After market: 1.2614 -0.04 (-3.34%)

Fundamental Rating

3

Overall HOTH gets a fundamental rating of 3 out of 10. We evaluated HOTH against 194 industry peers in the Pharmaceuticals industry. While HOTH has a great health rating, there are worries on its profitability. HOTH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HOTH had negative earnings in the past year.
HOTH had a negative operating cash flow in the past year.
HOTH had negative earnings in each of the past 5 years.
HOTH had a negative operating cash flow in each of the past 5 years.
HOTH Yearly Net Income VS EBIT VS OCF VS FCFHOTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

HOTH has a Return On Assets of -77.89%. This is in the lower half of the industry: HOTH underperforms 71.65% of its industry peers.
HOTH has a Return On Equity (-83.39%) which is in line with its industry peers.
Industry RankSector Rank
ROA -77.89%
ROE -83.39%
ROIC N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
HOTH Yearly ROA, ROE, ROICHOTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HOTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOTH Yearly Profit, Operating, Gross MarginsHOTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, HOTH has more shares outstanding
The number of shares outstanding for HOTH has been increased compared to 5 years ago.
There is no outstanding debt for HOTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HOTH Yearly Shares OutstandingHOTH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
HOTH Yearly Total Debt VS Total AssetsHOTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

HOTH has an Altman-Z score of 4.23. This indicates that HOTH is financially healthy and has little risk of bankruptcy at the moment.
HOTH has a Altman-Z score of 4.23. This is in the better half of the industry: HOTH outperforms 77.84% of its industry peers.
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACCN/A
WACCN/A
HOTH Yearly LT Debt VS Equity VS FCFHOTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 15.08 indicates that HOTH has no problem at all paying its short term obligations.
HOTH has a Current ratio of 15.08. This is amongst the best in the industry. HOTH outperforms 87.11% of its industry peers.
A Quick Ratio of 15.08 indicates that HOTH has no problem at all paying its short term obligations.
The Quick ratio of HOTH (15.08) is better than 87.11% of its industry peers.
Industry RankSector Rank
Current Ratio 15.08
Quick Ratio 15.08
HOTH Yearly Current Assets VS Current LiabilitesHOTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

HOTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.54%, which is quite impressive.
EPS 1Y (TTM)41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, HOTH will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.53% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.86%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HOTH Yearly Revenue VS EstimatesHOTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M
HOTH Yearly EPS VS EstimatesHOTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HOTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HOTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOTH Price Earnings VS Forward Price EarningsHOTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOTH Per share dataHOTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as HOTH's earnings are expected to grow with 13.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.4%
EPS Next 3Y13.53%

More info and screens

0

5. Dividend

5.1 Amount

HOTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOTH THERAPEUTICS INC

NASDAQ:HOTH (8/1/2025, 8:00:02 PM)

After market: 1.2614 -0.04 (-3.34%)

1.305

-0.03 (-1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners2.31%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap17.24M
Analysts82.5
Price Target4.59 (251.72%)
Short Float %3.05%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.7%
Min EPS beat(2)-1.81%
Max EPS beat(2)15.21%
EPS beat(4)3
Avg EPS beat(4)17.32%
Min EPS beat(4)-1.81%
Max EPS beat(4)45.28%
EPS beat(8)6
Avg EPS beat(8)21.7%
EPS beat(12)9
Avg EPS beat(12)14.55%
EPS beat(16)11
Avg EPS beat(16)12.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)31.71%
EPS NQ rev (3m)31.71%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.89%
ROE -83.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.08
Quick Ratio 15.08
Altman-Z 4.23
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
EPS Next Y42.86%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.9%
OCF growth 3YN/A
OCF growth 5YN/A